Minoryx inicia el ensayo de fase II/III del tratamiento para la adrenomieloneuropatía

by Minoryx Therapeutics

El primer paciente con esta enfermedad rara que ha iniciado el tratamiento con MIN-102 ha sido en el Hospital Vall d'Hebron de Barcelona. El estudio, denominado ADVANCE, reclutará en total a 100 paci...

Read more

Minoryx Therapeutics receives Orphan Drug Designation from the US FDA for its lead candidate MIN-102

by Professional Newco

MIN-102 targets X-linked Adrenoleukodystrophy (X-ALD), a life threatening orphan CNS disease with high unmet medical need. Orphan drug status for MIN-102 has now been granted by both the FDA and the E...

Read more

Minoryx Therapeutics Initiates Phase 1 clinical trial of MIN-102

by Ysios Capital

MIN-102 is a differentiated PPAR gamma agonist with a superior profile for central nervous system related diseases. It has shown robust preclinical proof of concept. The aim of the Phase 1 study is to...

Read more

Minoryx Therapeutics completes Series A funding of €19.4M ($21.7M)

by Ysios Capital

Ysios Capital, a Spanish investment fund, led the round. The fundraising was also supported by a substantial syndicate of new investors including Kurma Partners, Roche Venture Fund, Idinvest Partners ...

Read more
Subscribe to Directory
Write an Article

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

Santiago Ramón y Cajal: 'En la lucha c...

by Universidad de Zaragoza

El catedrático de Anatomía Patológica de la Universidad Autónoma d...

Photos Stream